SAGE(Delisted)
Sage TherapeuticsยทNASDAQ
--
--(--)
SAGE Profile
Sage Therapeutics, Inc.
A biopharmaceutical company that develops drugs to treat life-threatening, rare central nervos system disorders
215 First Street, Cambridge, Massachusetts 02142
--
Sage Therapeutics, Inc., was incorporated in Delaware on April 16, 2010. The company is a biopharmaceutical company with a mission to pioneer solutions that deliver life-changing brain health drugs so everyone can thrive. In addition to commercial products for postpartum depression, the company targets brain diseases and disorders in clinical development and early stages. As a company, the company focuses on brain health, and they are currently targeting two key central nervous system receptor systems, GABA and NMDA. The GABA receptor family is considered to be the main inhibitory neurotransmitter in the central nervous system, mediating downstream neural and bodily functions by activating GABAA receptors. The NMDA-type receptor of the glutamate receptor system is the main excitatory receptor system in the central nervous system. Dysfunction of these systems is associated with a wide range of central nervous system diseases.
